Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non-Small-Cell Lung Cancer JCO PRECISION ONCOLOGY Neal, J. W., Costa, D. B., Muzikansky, A., Shrager, J. B., Lanuti, M., Huang, J., Ramachandran, K. J., Rangachari, D., Huberman, M. S., Piotrowska, Z., Kris, M. G., Azzoli, C. G., Sequist, L., Chaft, J. E. 2021; 5: 325–32
View details for DOI 10.1200/PO.20.00301
View details for Web of Science ID 000636554600002